Exhibit 10.4
Confidential treatment has been requested for portions of this exhibit. The copy
filed herewith omits the information subject to the confidentiality request.
Omissions are designated as *. A complete version of this exhibit has been filed
separately with the Securities and Exchange Commission.
LICENSE AGREEMENT
THIS LICENSE AGREEMENT, dated as of August 28, 2002 (this "Agreement"),
is entered into by and between AnorMED Inc., a company incorporated in Canada
("AnorMED"), and Synergy Pharmaceuticals, Inc., a Delaware corporation
("Synergy").
RECITALS
X. Xxxxxxx Xxxxxxx Public Limited Company, an English corporation
("JM"), and SmithKline Xxxxxxx Corporation, a Pennsylvania corporation ("SKB"),
entered into a Cooperative Research and Assignment Agreement, dated as of
January 11, 1990 (the "Cooperative Agreement") for a joint research program
regarding the synthesis of certain non-metal compounds.
B. JM and AnorMED entered into an Asset Transfer Agreement, dated as of
June 28, 1996, whereby JM assigned to AnorMED all of its right, title and
interest in the Cooperative Agreement, including valuable patent rights,
technical data and information relating to the compound Atiprimod (a/k/a
Azaspiranes).
C. Effective November 4, 1996, SKB terminated the Cooperative Agreement
and assigned to AnorMED all of its right, title, and interest in the Cooperative
Agreement, including valuable patent rights, technical data and information
relating to the compound Atiprimod (a/k/a Azaspiranes).
D. Synergy desires to acquire from AnorMED, and AnorMED desires to
grant to Synergy, a license to develop, manufacture, have manufactured, use and
commercialize products incorporating Atiprimod (a/k/a Azaspiranes), upon the
terms and conditions set forth herein.
AGREEMENT
NOW, THEREFORE, the parties agree as follows:
1. DEFINITIONS
"Affiliate" shall mean any company or other business entity controlled
by, controlling or under common control with a party, control being presumed if
there is direct or indirect ownership of at least thirty-three and one-third
percent (33 1/3%) (or, if less, the maximum permitted by applicable law) of the
voting stock, equity or income interest.
"Final Product" shall mean any pharmaceutical composition approved for
sale as a drug in a country in the Territory by the appropriate agency or
governmental body in dosage form that contains a Licensed Compound and that is
packaged and labeled for sale to the ultimate customer for use in the Licensed
Field.
"Health Registration Application" shall mean, with respect to a country
in the Territory, an application for a Health Registration Approval. For the
purpose of Section 3, a Health Registration Application shall be deemed a
separate Health Registration Application for each therapeutic area (e.g.,
oncology, rhinitis, asthma, inflammatory bowel disease, rheumatoid arthritis or
chronic obstructive pulmonary disease (COPD)) covered by the Health Registration
Application whether filed as one or several applications.
"Health Registration Approval" shall mean, with respect to a country in
the Territory, the approval by the appropriate agency or governmental body
required to manufacture, distribute, sell and market a Final Product in that
country. For the purpose of Section 3, a Health Registration Approval shall be
deemed a separate Health Registration Approval for each therapeutic area (e.g.,
oncology, rhinitis, asthma, inflammatory bowel disease, rheumatoid arthritis or
chronic obstructive pulmonary disease (COPD)) covered by the Health Registration
Approval whether given as one or several approvals.
"Licensed Compound" shall mean Atiprimod (a/k/a Azaspiranes) and any
analogs or derivatives described in the Patent Rights.
"Licensed Field" shall mean the diagnosis, treatment and prevention of
disease in humans.
"Net Sales" shall mean the gross invoiced amount for Final Product sold
or otherwise transferred by Synergy, its Affiliates or its sublicenses (other
than Qualifying Sublicensees, as defined in Section 2.2(a)) less:
(a) any trade, cash or quantity discounts actually allowed;
(b) credits or allowances actually granted upon claims, rejections,
returns or retroactive price adjustments of Final Product; and
(c) customs duties and taxes based on gross sales included in and
separately stated on the invoice, as adjusted for rebates and refunds (but not
including taxes assessed on income).
Any Final Product sold or otherwise transferred in other than an arm's
length transaction or for other property (e.g., barter) shall be deemed invoiced
at its fair market price in the country of sale or transfer. "Net Sales" shall
exclude (i) the transfer of free samples of Final Product and, prior to
marketing, clinical trial materials and (ii) sales or transfers of Final Product
among Synergy, its Affiliates and its sublicensees unless the receiving party is
the consumer or user of the Final Product; however, the resale or retransfer of
such Final Product to a third party shall be included in "Net Sales."
"Patent Rights" shall mean all the patents and patent applications of
AnorMED set forth in Exhibit A attached hereto, together with all divisionals,
extensions, reissues, substitutions, renewals, continuations and foreign
counterparts thereof (including European Supplementary Protection Certificates)
and patents issuing thereon.
2
"Technical Information" shall mean all trade secrets, technical reports
and data concerning the Licensed Compound or Final Product that are necessary to
develop, manufacture, have manufactured, use or commercialize Final Product in
the Territory for the Licensed Field, including, but not limited to, preclinical
data, toxicological studies, methods of synthesis, assay information and
clinical trial data.
"Territory" shall mean all countries of the world.
"Valid Patent Claim" shall mean either (a) a claim of an issued and
unexpired patent included in the Patent Rights that has not been held
unenforceable, unpatentable or invalid in a decision of a court or other
governmental agency of competent jurisdiction, unappealable or unappealed within
the time allowed for appeal, and which has not been admitted to be invalid or
unenforceable through reissue or disclaimer or otherwise or (b) a claim of a
pending patent application included in the Patent Rights that has not been
canceled, withdrawn, abandoned or rejected in a decision of a court or other
governmental agency of competent jurisdiction, unappealable or unappealed within
the time allowed for appeal; provided that no more than eight (8) years has
passed since the filing date of such patent application.
2. GRANT OF RIGHTS
2.1 Patent License
Subject to the terms of this Agreement, AnorMED hereby grants to
Synergy an exclusive license under the Patent Rights, together with related
Technical Information, to develop, manufacture, have manufactured, use, sell,
offer to sell and import Final Product in the Territory for the Licensed Field,
including the right to manufacture or have manufactured Licensed Compound for
such Final Product. Synergy shall not use the Patent Rights, together with
related Technical Information, for any purpose other than that described in the
preceding sentence. After execution of this Agreement, AnorMED shall promptly
deliver to Synergy all current written forms of the Technical Information.
2.2 Sublicensing by Synergy
(a) Synergy may sublicense its rights granted pursuant to Section 2.1.
If Synergy sublicenses substantially all of the rights pursuant to Section 2.1
to one or more third parties that are not an Affiliate of Synergy at the time of
such sublicensing (a "Qualifying Sublicensee"), (i) the royalties and milestone
payments due from the Qualifying Sublicensee shall be no less than those set
forth in this Agreement and (ii) Synergy shall pay AnorMED * percent of any and
all income and other consideration (e.g.;, equity, consulting fees and payments
for supplies) received by Synergy from such Qualifying Sublicensee.
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
3
(b) Each sublicense shall be subject to and consistent with the terms
of this Agreement and shall be terminable at AnorMED's option upon termination
of this Agreement. Synergy shall promptly inform AnorMED of the execution,
scope, amendment of scope and termination of each sublicense and the name and
address of each sublicensee.
3. MILESTONE PAYMENTS
In consideration of the license granted herein, Synergy shall pay to
AnorMED the following amounts upon the occurrence of each milestone indicated
below (whether the milestone is achieved by Synergy, its Affiliates or
sublicensees (other than a Qualifying Sublicensee):
Milestone Payment to AnorMED by Synergy
--------- ------------------------------
* US$*
* US$*
* US$*
* US$*
All payments shall be made within thirty (30) days following the
occurrence of the milestone indicated by wire transfer to an account designated
by AnorMED. All the above payments are nonrefundable and are not creditable
against royalties.
4. ROYALTIES
4.1 Amount
In consideration of the license granted herein, Synergy shall pay
AnorMED the following royalty on Net Sales in the Territory during the term of
this Agreement even though the Final Product may have different indications,
formulation, unit size, etc.
Net Sales During Calendar Year Royalty Rate
------------------------------ ------------
$0 to US$* *%
Above US$* and at or below US$* *%
Above US$* and at or below US$* *%
Above US$* *%
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
4
For example, if Net Sales during the calendar year are US$*), the total
royalties to be paid would equal US$* (i.e., * of US$*, plus* of US$*, plus * of
US$*, plus * of US$*).
4.2 Patent Coverage and Generic Competition; Reduction in Royalty
On a quarter-by-quarter basis, Net Sales of a particular Final Product
in any country in which:
(a) there is not a Valid Patent Claim covering such Final
Product; and
(b) there is competition to such Final Product from a product
incorporating as an active component a compound identical to the
Licensed Compound in such Final Product
shall not be aggregated with other Net Sales for the purpose of calculating the
royalty payable under Section 4.1. Instead, a royalty of * percent shall be
payable in respect of such Net Sales. For the purpose of this Section 4.2, a
product shall be in competition with a Final Product if the market share of such
product in the country and quarter in question is * percent or more of the total
market for all products incorporating as an active component a compound
identical to the Licensed Compound incorporated as an active component in such
Final Product.
4.3 Payment; Reports
Royalties shall be paid to AnorMED within thirty (30) days after the
end of each calendar quarter by wire transfer to an account designated by
AnorMED. With each payment, Synergy shall provide AnorMED with a written report
of (a) Net Sales (in local currency and United States dollars, with applicable
exchange rates pursuant to Section 4.4 noted) and the number of units sold
during each month of the quarter for each type of Final Product by country and
(b) a calculation of the royalties due thereon and aggregate royalties due.
4.4 Currency Conversion
Royalties shall be calculated and paid in United Stated dollars. For
the purpose of computing the Net Sales made in a currency other than United
States dollars, Synergy shall convert such currency from local currency to
United States dollars on a monthly basis using the average of the relevant
exchange rate published by The Wall Street Journal for the first five (5) days
of the relevant month.
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
5
4.5 Books and Records
Synergy shall keep, or cause to be kept, accurate books and records in
sufficient detail to verify the calculation of royalties and the reports given
hereunder and shall retain such books and records at its principal place of
business for at least five (5) years after the end of the fiscal year to which
they pertain. AnorMED shall have the right, at its expense and not more
frequently than once per calendar year, to have its accountants and/or auditors
examine, during normal business hours, the books and records of Synergy, its
Affiliates and its sublicensees relating to the calculation of royalties and
reports given hereunder for any period during which Synergy is to keep the books
and records. If such examination discovers an error in excess of five percent
(5%) for the period under review, Synergy shall reimburse AnorMED for its
reasonable costs of examination.
5. WITHHOLDING
If applicable law requires the withholding of taxes on amounts paid to
AnorMED hereunder, Synergy will have the right to withhold such taxes; provided
that Synergy shall pay the amount withheld to the proper taxing authority on
behalf of AnorMED and shall promptly secure and send to AnorMED proof evidencing
the payment of such taxes. Synergy agrees to assist AnorMED in claiming
exemption under any applicable income tax treaty from any such withholding.
6. ASSISTANCE FROM ANORMED
As needed and upon reasonable request of Synergy, AnorMED will arrange
to make certain of its scientific personnel available to Synergy for assistance
in the development of the Licensed Compound at an approximate yearly rate of
US$* per full-time equivalent (adjusted annually for cost-of-living increases),
payment by Synergy for such assistance to be within thirty (30) days of invoice
and invoices shall be issued quarterly at the end of each calendar quarter.
Assistance by AnorMED shall be subject to the availability of its scientific
personnel. In no event shall AnorMED be required to prejudice its own research
and development programs to provide assistance to Synergy.
7. DILIGENCE
7.1 Responsibilities
Synergy shall be responsible, at its expense, for all development and
commercialization activities related to Licensed Compound and Final Product,
including, but not limited to, preclinical development, clinical trials,
regulatory strategy, applications for regulatory approval, manufacturing,
marketing and sales.
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
6
7.2 Efforts
Synergy shall use commercially reasonable and diligent efforts to
develop, register, manufacture, promote, market, distribute and sell Final
Product for the Licensed Field within the Territory.
7.3 Reports
In order to inform AnorMED of the progress of the Atiprimod (a/k/a
Azaspiranes) project, Synergy shall submit to AnorMED, during the term of this
Agreement, a written report within three months after the end of each calendar
year which covers, without omission of any relevant information, the then
current technical status, the results achieved, the problems being encountered
and other pertinent information relating to the development and manufacturing of
Final Product, including, but not limited to, all clinical data, clinical
protocols and regulatory filings in the Territory. Synergy shall submit to
AnorMED summary updates of each annual report on a quarterly basis. In addition,
Synergy shall report all material events and results relating to the Atiprimod
(a/k/a Azaspiranes) project (e.g., results of clinical trials, results of
toxicology or stability studies, or unexpected, serious or severe adverse
events) promptly following their occurrence or receipt.
7.4 Maintenance Fee
Commencing on January 1, 2004, and on January 1 of each subsequent
calendar year during the term of this Agreement, Synergy shall pay AnorMED a
maintenance fee of two hundred thousand ($200,000) in United States dollars;
provided that the maintenance fee shall not be due on or after the first January
1 following the payment of royalties under this Agreement in excess of two
hundred thousand United States dollars (US$200,000). Failure to pay the
maintenance fee when due will be a material breach of this Agreement.
8. CONFIDENTIALITY; PRESS RELEASES
8.1 Confidential Information
Except as otherwise provided in this Section 8, during the term of this
Agreement and for a period of five (5) years thereafter, each party shall keep
confidential and not disclose or use (except as contemplated by this Agreement)
any proprietary or confidential information received from the other party,
including Technical Information. This restriction shall not apply to any
information to the extent it (a) is already known to the recipient at the time
of disclosure (as may be verified by the recipient's contemporaneous written
records), (b) is or becomes public knowledge through no fault of the recipient,
(c) is received without an obligation of confidentiality from a third party
having the lawful right to disclose same, or (d) was independently developed or
discovered by the recipient without the use of the information disclosed by the
disclosing party (as may be verified by the recipient's contemporaneous written
records).
7
8.2 Authorized Disclosure
Each party may disclose information received from the other party (a)
to third parties under appropriate terms and conditions, including
confidentiality provisions substantially equivalent to this Section 8, for
consulting, manufacturing, development, sublicensing, external testing and
marketing trials with respect to Licensed Compound or Final Product or an
investment in a party's capital stock and (b) to the extent such disclosure is
reasonably necessary, in connection with submissions to regulatory authorities
for purposes of this Agreement, filing or prosecuting patent applications
contemplated under this Agreement, prosecuting or defending litigation,
complying with applicable governmental regulations or conducting preclinical or
clinical trials of Licensed Compound or Final Product; provided, however, that
in the event of any proposed disclosure described in clause (b), the disclosing
party will, except where impracticable (e.g., medical emergencies), give
reasonable advance notice to the other party of such disclosure requirement and
will use its reasonable efforts to secure confidential treatment of the
information to be disclosed.
8.3 Scientific Publications
Except as required by law, regulation or court order, neither party
shall publish or make a presentation of any confidential or proprietary
information it has created or developed with respect to the development of
Licensed Compound or Final Product, including the Technical Information, or the
results of any preclinical or clinical studies or investigations it has
conducted or had conducted with respect to Licensed Compound or Final Product,
without the prior written consent of the other party, which consent shall not be
unreasonably withheld.
8.4 Public Announcements
Except to the extent required by applicable law or regulations, in the
reasonable judgment of a party, or to the extent the substance thereof has
previously been reviewed and released by the parties or is in the public domain
through no fault of the originating party, neither party shall make any
announcement, news release, public statement, publication or presentation
regarding the material terms of this Agreement without the prior written consent
of the other party, which consent shall not be unreasonably withheld. The
parties will consult with one another regarding the provisions of this Agreement
to be redacted in any filing made by the parties with regulatory agencies (e.g.,
Securities Commission) or as otherwise required by law. The parties will use
reasonable efforts to coordinate the initial announcement or press release
relating to this Agreement such that each party's initial announcement or press
release may be made contemporaneously.
9. ANORMED PATENTS
9.1 Prosecution
AnorMed shall diligently prosecute and take all reasonable steps
required to maintain in full force and effect and defend the Patent Rights in
the Licensed Field and Territory. Defending the Patent Rights includes, for
example, interference and opposition proceedings pertaining to patent
applications or patents, but does not include enforcing the Patent Rights
against third party infringers, which is covered by Section 9.2. All
out-of-pocket costs after the date of this Agreement, including, but not limited
to, outside attorneys', translation, filing and maintenance fees and costs in
connection therewith, shall be paid by Synergy to AnorMED within thirty (30)
days of invoice. AnorMED shall provide Synergy with an opportunity to review and
comment on the nature and text of any new or pending patent applications for all
Patent Rights in the Territory. AnorMED shall consider in good faith any
comments from Synergy regarding steps that might be taken to strengthen the
Patent Rights being licensed to Synergy hereunder and shall, on a reasonable
basis, conduct discussions with Synergy, at its request, regarding the patent
prosecution strategy for the Patent Rights. If AnorMED shall elect not to
prosecute, maintain or defend any Patent Rights in any country in the Territory,
Synergy shall be entitled to do so at its expense and AnorMED agrees, without
charge, to render such reasonable assistance, execute any documents and do such
other acts as may be reasonably necessary in connection with the prosecution,
maintenance or defense of any Patent Rights as Synergy may reasonably requests.
8
9.2 Third Party Infringement
Each party shall promptly notify the other party in writing of any
alleged or threatened infringement of a patent included in the Patent Rights.
Synergy shall have the first right, but not the obligation, to take and control
all legal action necessary, at its expense, to enforce the Patent Rights against
any infringer in the Licensed Field and Territory that is or could be adversely
impacting its rights hereunder. If, after sixty (60) days' notice, Synergy has
not brought a suit or action against such infringer, then AnorMED shall, in its
sole discretion, have the right to take such legal action as it deems necessary
or desirable, at its expense. Each party agrees, without charge, to render such
reasonable assistance, execute any documents and do such other acts as may be
reasonably necessary in such legal action as the other party may reasonably
request.
After reimbursing the parties of their out-of-pocket costs from any
recovery, including, but not limited to, reasonable attorneys' fees, the balance
of any recovery related to such infringement shall be split as follows: fifty
percent (50%) to Synergy and fifty percent (50%) to AnorMED.
9.3 Patent Markings
Synergy shall cause all Final Product to be marked with applicable
Patent Rights in accordance with applicable patent laws.
9.4 Patent Term Extension
Synergy shall within thirty (30) days of obtaining any Health
Registration Approval provide to AnorMED any information required by AnorMED to
apply for a European Supplementary Protection Certificate or other patent term
extension in respect of the Final Product covered by the Health Registration
Approval in the country or countries covered by the Health Registration
Approval.
10. TRADEMARKS AND CORPORATE NAME
All trademarks (except the "ANORMED" xxxx) to be utilized by Synergy
and/or its Affiliates with Final Product under this Agreement shall be owned by
Synergy and/or its Affiliates. Except to the extent prohibited by applicable
law, Final Product covered by this Agreement shall bear AnorMED's corporate name
in a reasonable location on outer packaging labels and on any package inserts.
Synergy shall mention, in certain appropriate forms of its advertising and
promotional literature, AnorMED's contribution to the development of each Final
Product. The first use of any such reference shall require AnorMED's approval,
which shall not be unreasonably withheld.
9
11. WARRANTIES; DISCLAIMER; LIMITATION OF LIABILITY
11.1 Both Parties
Each party represents and warrants to the other that (a) it has full
right, power and authority to enter into this Agreement and to carry out the
provisions hereof and (b) it has all necessary corporate approvals for its
execution, delivery and performance of this Agreement.
11.2 AnorMED
AnorMED represents and warrants that it has full rights to the Patent
Rights.
11.3 Disclaimer
EXCEPT FOR THE WARRANTIES SET FORTH IN SECTIONS 11.1 AND 11.2, ANORMED
MAKES NO OTHER REPRESENTATIONS OR WARRANTIES WITH RESPECT TO THE PATENT RIGHTS
AND TECHNICAL INFORMATION AND EXPRESSLY DISCLAIMS ANY OTHER WARRANTIES, EXPRESS
OR IMPLIED, INCLUDING, WIHTOUT LIMITATION, WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, PATENTABILITY AND NONINFRINGEMENT OF
INTELLECTUAL PROPERTY RIGHTS OF OTHER PARTIES.
11.4 Limitation of Liability
(a) AnorMED shall have no liability whatsoever to Synergy or any other
person for or on account of any injury, loss, damage, of any kind or nature,
sustained by, or damage assessed or asserted against, or any other liability
incurred by or imposed upon Synergy or any other person, arising out of or in
connection with or resulting from (i) the development, production, use or sale
of any Licensed Compound or Final Product, or the practice of the Patent Rights,
or (ii) any advertising or other promotional activities with respect to any of
the foregoing.
(b) In no event shall AnorMED be liable for any incidental, special,
indirect or consequential damages resulting from any reason whatsoever. This
exclusion applies to all legal theories under which damages may be sought.
12. INDEMNIFICATION
Synergy shall indemnify and hold AnorMED, its officers, directors,
employees, agents, consultants and contractors (the "Indemnified Parties")
harmless from and against any claim, action, liability, damage, loss, cost or
expense (including reasonable attorneys' fees) ("Loss") arising from or related
to the exercise of the license granted herein, unless and to the extent such
Loss arises from or is related to the gross negligence or willful default or
fraud of the Indemnified Parties. AnorMED shall promptly notify Synergy of any
such claim or action, allow Synergy to control the defense of such claim or
action and render all reasonable assistance to Synergy in connection with
defending such claim or action. Synergy shall secure and maintain product
liability insurance commensurate with the reasonable standards of the industry
with respect to Final Product. Upon request, Synergy shall provide AnorMED with
evidence of such insurance coverage.
10
13. TERM AND TERMINATION
13.1 Expiration
Unless terminated earlier pursuant to Section 13.2 through 13.4 or
14.15, this Agreement shall expire upon the last to expire of any patents
included in the Patent Rights. Upon expiration (but not earlier termination) of
this Agreement, Synergy's license to use the Technical Information pursuant to
Section 2.1 shall become fully paid-up, royalty-free and nonexclusive and shall
survive.
13.2 Termination for Convenience
Synergy may terminate this Agreement for any reason or no reason on
ninety (90) days' written notice to AnorMED.
13.3 Insolvency
If either party shall become insolvent or make an assignment for the
benefit of creditors, or if proceedings in voluntary or involuntary bankruptcy
shall be instituted on behalf of or against such party, or if a receiver or
trustee of such party's property shall be appointed, the other party shall have
the right to terminate this Agreement at any time by written notice to the
insolvent party.
13.4 Breach
Each party shall have the right to terminate this Agreement after
appropriate written notice to the other party in the event the other party is in
material breach of this Agreement (including failure to timely pay any amounts
due hereunder), unless the other party cures such breach within thirty (30) days
(or ten (10) days in the case of failure to pay any amount due) after the date
of notice; provided, however, that any such termination shall not release either
party from any obligations accrued prior thereto.
11
13.5 Inventory of Final Product
Synergy shall have a period of twelve (12) months following expiration
or termination of this Agreement to sell any Final Product held in inventory
remaining at the date of termination, subject to the payment of royalties in
accordance with Section 4. At the end of such twelve (12) month period, AnorMED
shall have the option but not the obligation to purchase any Final Product still
held in inventory by Synergy for a price equal to *.
13.6 Return of Technical Information
Upon expiration (pursuant to Section 13.1) or earlier termination
(pursuant to Section 13.2 through 13.4 or 14.15) of this Agreement, Synergy
shall (at its expense):
(a) Cause all materials containing any Technical Information to be
promptly returned to AnorMED.
(b) Return or destroy, at AnorMED's option, all bulk Licensed Compound.
(c) Assign to AnorMED all rights in all pre-clinical studies, clinical
trials or regulatory applications or approvals (e.g., investigational new drug
applications). Within thirty (30) days after such assignment, AnorMED shall
elect which of the preclinical studies, clinical trials or regulatory
applications or approvals will be continued and which will be discontinued
thereafter Synergy shall, promptly following demand therefore, reimburse AnorMED
for all costs and charges incurred in connection with those pre-clinical
studies, clinical trials or regulatory applications or approvals AnorMED elects
to discontinue, including all wind down costs and charges.
(d) During the four (4) months following termination, discuss with
AnorMED information and data that exists with respect to Licensed Compound and
Final Product and provide to AnorMED such relevant information and data
requested by AnorMED.
13.7 Synergy Developments
In the event of termination of this Agreement for reasons other than
insolvency of AnorMED or material breach by AnorMED pursuant to Section 13.3 or
13.4, AnorMED shall be granted a fully paid-up, royalty-fee, worldwide,
nonexclusive license, with right to sublicense, to develop, manufacture, have
manufactured, use, sell, offer to sell and import Final Product in the Territory
for the Licensed Field using any inventions, developments or other Technical
Information, including patents and copyrights, developed for or incorporated in
Final Product by Synergy or its Affiliates or sublicensees.
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
12
13.8 Survival
The rights and obligations of Sections 4.5, 8.1, 11.4, 12, 13.1 (second
sentence), 13.5, 13.6, 13.7 and 14 and any accrued obligations shall survive
termination or expiration of this Agreement. All other rights and obligations
shall not survive termination or expiration.
14. MISCELLANEOUS
14.1 Assignment
Neither this Agreement nor any right or obligation arising hereunder
may be assigned or delegated in whole or in part by either party without the
prior written consent of the other party, except to a successor or purchaser of
all or substantially all the assets of the party related to its pharmaceutical
business or, in the case of AnorMED, to a wholly-owned subsidiary of AnorMED,
provided, that, in the event of an assignment by AnorMED to a wholly owned
subsidiary, AnorMED shall guarantee the full performance of this Agreement by
the subsidiary. Any assignment or delegation that is not exempted and that is
attempted without such consent shall be of no force or effect. This Agreement
shall be binding on and inure to the benefit of the successors and permitted
assigns of the parties.
14.2 Entire Agreement; Modification
This Agreement constitutes the entire understanding between the parties
hereto with respect to the subject matter hereof and supersedes and cancels all
prior understandings, promises and agreements, including the Term Sheet, dated
June 27, 2002; provided that Synergy's obligation to make the payments described
under the heading "Exclusivity" shall survive. No modifications or amendment
hereof shall be valid or binding on the parties unless made in writing and duly
executed by the parties.
14.3 Notices and Communications
Any notice or any other communication required or permitted to be given
to a party pursuant hereto shall be sufficiently given if delivered personally
or by facsimile or express courier service (expenses prepaid) to the address set
forth below:
AnorMED: AnorMED Inc.
Xxxxx #000
00000 - 00xx Xxxxxx
Xxxxxxx, XX
X0X IN5 Canada
Attn: President
FAX: (000) 000-0000
13
Synergy: Synergy Pharmaceuticals, Inc.
0 Xxxxxxxxx Xxxxx, Xxxxx 000
Xxxxxxxx, XX 00000
Attn: President
FAX: (000) 000-0000
or to such other address as the party shall designate by written notice given to
the other party. All notices, information, reports and other communications in
connection with this Agreement shall be in English.
14.4 Separability
If any provision of this Agreement shall be held to any extent invalid
or unenforceable, such provision shall be deemed amended to conform to
applicable laws and to accomplish the intentions of the parties.
14.5 Waivers
No waivers of any right under this Agreement shall be deemed effective
unless contained in a writing signed by the party charged with such waiver, and
no waiver of any right arising from any breach or failure to perform shall be
deemed to be a waiver of any future right or of any other right arising under
this Agreement.
14.6 Counterparty
This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute
one and the same instrument.
14.7 Review of Agreement
This Agreement has been submitted to the scrutiny of both parties and
their counsel and shall be given a fair and reasonable interpretation in
accordance with the words hereof, without consideration or weight being given to
its being drafted by or for one of the parties.
14.8 Payments
All payments due under this Agreement shall be paid in United States
dollars and made by wire transfer. Any payments that are overdue shall be
charged interest at the prime rate as quoted by the Royal Bank of Canada on the
first business day of each month plus five (5) percentage points or the maximum
permitted by applicable law, whichever is less.
14.9 Compliance with Law; Export Regulations
In the performance of this Agreement, each party shall comply with all
laws, regulations, rules, orders and other requirements, now or hereafter in
effect, of governmental authorities having jurisdiction. This Agreement and any
Technical Information provided hereunder are subject to restrictions concerning
the export of information and materials that may be imposed by a government.
Accordingly, Synergy agrees that it will not export, directly or indirectly, any
information or materials acquired under this Agreement or any products utilizing
any such information or materials to any country for which a government or any
agency thereof at the time of export requires an export license or other
governmental approval, without first obtaining the written consent to do so from
the appropriate agency of the government when required by an applicable statute
or regulation.
14
14.10 Independent Contractors
The parties are and shall be independent contractors. The relationship
between the parties created by this Agreement shall not constitute a
partnership, joint venture or agency. Neither party shall have the authority to
make any statements, representations or commitments of any kind, or to take any
action, that shall be binding on the other party.
14.11 Nonsolicitation
During the first eight (8) years after the date of this Agreement,
Synergy shall not solicit or seek to induce any employee of or consultant to
AnorMED to terminate his or her relationship with AnorMED and to seek employment
or an independent consulting relationship with Synergy or any of its Affiliates
or sublicensees.
14.12 Governing Law
This Agreement shall be governed by and construed in accordance with
the laws of the State of Washington, U.S.A. (regardless of its or any other
state's choice of law provisions).
14.13 Jurisdiction and Venue
Any legal action with respect to this Agreement shall be instituted in
a provincial court of general jurisdiction in British Columbia, Canada, the
parties hereby consenting to the jurisdiction and venue of such court.
14.14 Payments to GlaxoSmithKline
All costs and expenses associated with obtaining Atiprimod drug
substance or product or information related to Atiprimod from SmithKline Xxxxxxx
(a/k/a GlaxoSmithKline) incurred after the date hereof will be paid by Synergy
to AnorMED within thirty (30) days of invoice.
15
14.15 Force Majeure
Either party shall be excused from performance under this Agreement to
the extent such performance is prevented because of governmental action or
inaction, war, act of terrorism, fire, explosion, flood, strike, peril of the
sea, lockout, embargo, act of God, or any other cause beyond the control and
without the fault or negligence of the party claiming the force majeure event;
provided that the party claiming the force majeure event has exerted all
reasonable efforts to avoid or remedy such force majeure event. The excuse for
performance shall continue as long as the force majeure event continues. Upon
the cessation of the force majeure event, the party claiming the force majeure
shall promptly resume performance under this Agreement. If the force majeure
event continues for a period of one hundred and twenty (120) days, AnorMED shall
have the right to terminate this Agreement upon a further thirty (30) days'
written notice to Synergy.
IN WITNESS WHEREOF, the parties have caused this Agreement to be duly
executed as of the day and year first above written.
ANORMED INC.
By: /s/ Xxxxxxx Xxxxxx
---------------------------
Dr. Xxxxxxx Xxxxxx
President
SYNERGY LIMITED
By: /s/ Xxxxxx Xxxxxx
---------------------------
Xx. Xxxxxx Xxxxxx
President
16
EXHIBIT A
PATENT RIGHTS
1. Title: Immunomodulatory Azaspiranes
Priority Application: USSN 712.325 7 June 1991
-------------------------------------------------------------------------------------------------------------------
Reference No. Territory Application No. Filing Date Issue Date Patent No. or
Publication
No.
-------------------------------------------------------------------------------------------------------------------
20015.00 US 07/712,325 7-Jun-91
Abandoned
-------------------------------------------------------------------------------------------------------------------
20015.01 US 07/981,147 24-Nov-92
Abandoned
-------------------------------------------------------------------------------------------------------------------
20015.20 US 08/277,456 19-Jul-94 7-Jan-97 US 5,591,748
-------------------------------------------------------------------------------------------------------------------
20015.40 PCT PCT/US92/04834 5-Jun-92 WO
92/22294
-------------------------------------------------------------------------------------------------------------------
20015.41 EPO 92914312.1 5-Jun-92
-------------------------------------------------------------------------------------------------------------------
20015.42 Ireland 921,827 1-Jul-92
-------------------------------------------------------------------------------------------------------------------
20015.43 Japan 500972/1993 5-Jun-92 2-Feb-01 3155277
-------------------------------------------------------------------------------------------------------------------
20015.44 S. Korea 93-703765 5-Jun-92 13-Jan-00 251570
-------------------------------------------------------------------------------------------------------------------
20015.45 Xxxxxx 000000 5-Jun-92
Abandoned
-------------------------------------------------------------------------------------------------------------------
20015.46 New Zealand 243,029 5-Jun-92 29-Nov-94 243029
Abandoned
-------------------------------------------------------------------------------------------------------------------
20015.47 Portugal 100,566 4-Jun-92
-------------------------------------------------------------------------------------------------------------------
20015.48 Abandoned S Africa 92/4107 5-Jun-92 28-Apr-93
-------------------------------------------------------------------------------------------------------------------
17
2. Title: Cytokine Inhibitors
Priority Application: USSN 657,578 19 February 1991
-------------------------------------------------------------------------------------------------------------------
Reference No. Territory Application No. Filing Date Issue Date Patent No. or
Publication
No.
-------------------------------------------------------------------------------------------------------------------
20019.00 Abandoned US 07/657,578 19-Feb-91
-------------------------------------------------------------------------------------------------------------------
20019.01 Con 01 US 07/887,628 22-May-92
Abandoned
-------------------------------------------------------------------------------------------------------------------
20019.02 Con 01 US 08/138,178 15-Oct-93 11-Feb-97 US 5,602,166
-------------------------------------------------------------------------------------------------------------------
20019.03 Con 02 US 08/779,418 7-Jan-97 4-May-99 US 5,900,430
-------------------------------------------------------------------------------------------------------------------
20019.20 CIP 02 US 08/469,415 6-Jun-95
Abandoned
-------------------------------------------------------------------------------------------------------------------
20019.40 PCT PCT/US92/01283 18-Feb-92 WO
92/14462
-------------------------------------------------------------------------------------------------------------------
20019.41 Australia 1463392 18-Feb-92 11-Jul-95 657745
-------------------------------------------------------------------------------------------------------------------
20019.42 Canada 2,104,214 18-Feb-92
-------------------------------------------------------------------------------------------------------------------
20019.43 European Patent Office 929073625 18-Feb-92 17-Nov-99 0 572537B1
-------------------------------------------------------------------------------------------------------------------
20019.44 Ireland 920508 18-Feb-92
-------------------------------------------------------------------------------------------------------------------
20019.45 Japan 04-507323/1992 18-Feb-92 23-Feb-0l 0162071
-------------------------------------------------------------------------------------------------------------------
20019.46 Abandoned S Korea 93-702468 18-Feb-92
-------------------------------------------------------------------------------------------------------------------
20019.47 S Africa 92/1120 17-Feb-92 27-Jan-93 92/1120
-------------------------------------------------------------------------------------------------------------------
20019.48 Austria 92907362.5 18-Feb-92 17-Nov-99 572537
-------------------------------------------------------------------------------------------------------------------
20019.49 Belgium 92907362.5 18-Feb-92 17-Nov-99 572537
-------------------------------------------------------------------------------------------------------------------
20019.50 Switzerland/Liechtenstein 92907362.5 18-Feb-92 17-Nov-99 572537
-------------------------------------------------------------------------------------------------------------------
20019.51 Denmark 92907362.5 18-Feb-92 17-Nov-99 572537
-------------------------------------------------------------------------------------------------------------------
20019.52 Spain 92907362.5 18-Feb-92 17-Nov-99 5172537
-------------------------------------------------------------------------------------------------------------------
20019.53 France 92907362.5 18-Feb-92 17-Nov-99 572537
-------------------------------------------------------------------------------------------------------------------
20019.54 Great Britain 92907362.5 18-Feb-92 17-Nov-99 572537
-------------------------------------------------------------------------------------------------------------------
20019.55 Greece 92907362.5 18-Feb-92 17-Nov-99 20000400311
-------------------------------------------------------------------------------------------------------------------
20019.56 Italy 92907362.5 18-Feb-92 17-Nov-99 572537
-------------------------------------------------------------------------------------------------------------------
20019.57 Luxembourg 92907362.5 18-Feb-92 17-Nov-99 572537
-------------------------------------------------------------------------------------------------------------------
20019.58 Monaco 92907362.5 18-Feb-92 17-Nov-99 572537
-------------------------------------------------------------------------------------------------------------------
20019.59 Netherlands 92907362.5 18-Feb-92 17-Nov-99 572537
-------------------------------------------------------------------------------------------------------------------
20019.60 Sweden 92907362.5 18-Feb-92 17-Nov-99 572537
-------------------------------------------------------------------------------------------------------------------
20019.61 Germany 92907362.5 18-Feb-92 17-Nov-99 P69230
314.6-08
-------------------------------------------------------------------------------------------------------------------
20019.62 Hong Kong 981133586.6
-------------------------------------------------------------------------------------------------------------------
18
3. Title: 2-[2-(Dimethylamino)ethyl]-8,8-dipropyl-
2-azaspiro[4.5]decane dimaleate
Priority Application: U.S. provisional 60/016,066 23 April 1996
U.S. provisional 60/001,134 13 July 1995
--------------------- ------------------ ------------------- ------------------ ------------------- ------------------
Reference Territory Application No. Filing Date Issue Date Patent No.
--------------------- ------------------ ------------------- ------------------ ------------------- ------------------
20021.00 (US) 08/981,929 11-Jul-96 14-Sep-99 US 5,952,365
--------------------- ------------------ ------------------- ------------------ ------------------- ------------------
19
4. Title: N,N-dimethyl-8,8-dipropyl-2-azaspiro
[4.5]decane-2-propanamine dimaleate
Priority Application: U.S. provisional 60/001,138 13 July 1995
U.S. provisional 60/015,996 23 April 1996
-----------------------------------------------------------------------------------------------------------------
Reference No. Territory Application No. Filing Date Issue Date Patent No.
or
Publication
No.
-----------------------------------------------------------------------------------------------------------------
20024.00 US 08/981,928 12-Jul-96 17-Aug-99 US 5,939,450
-----------------------------------------------------------------------------------------------------------------
20024.40 PCT PCT/US96/11590 12-Jul-96 WO
97/02820
-----------------------------------------------------------------------------------------------------------------
20024.41 Abandoned S Africa 96/5883 11-Jul-96 28-May-97 96/5883
-----------------------------------------------------------------------------------------------------------------
20024.42 Abandoned EPO 969260769 12-Jul-96 837678
-----------------------------------------------------------------------------------------------------------------
20024.43 Japan 09-505996 12-Jul-96 1 June-01 3195364
-----------------------------------------------------------------------------------------------------------------
19
5. Title: N, N-diethy]-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine
Priority Application: U.S. provisional 60/001,139 13 July 1995
U.S. provisional 60/016,065 23 April 1996
--------------------------------------------------------------------------------------------------------------------
Reference No. Territory Application No. Filing Date Issue Date Patent No. or
Publication
No.
--------------------------------------------------------------------------------------------------------------------
20029.00 US 08/679,480 12-Jul-96 28-Apr-98 US 5,744,495
--------------------------------------------------------------------------------------------------------------------
20029.40 Abandoned Xxxxxxx 00000 9-Jul-96
--------------------------------------------------------------------------------------------------------------------
20029.41 Argentina 960103537 11-Jul-96
--------------------------------------------------------------------------------------------------------------------
20029.42 Australia 5945596 11-Jul-96 8-Jun-00 716256
--------------------------------------------------------------------------------------------------------------------
20029.43 Abandoned Barbados 81402 12-Jul-96
--------------------------------------------------------------------------------------------------------------------
20029.44 Brazil 96019093 3-Jul-96
--------------------------------------------------------------------------------------------------------------------
20029.45 Bulgaria 100710 8-Jul-96 25-Feb-99 62359
--------------------------------------------------------------------------------------------------------------------
20029.46 Canada 2,181,006 11-Jul-96
--------------------------------------------------------------------------------------------------------------------
20029.47 Chile 123696 12-Jul-96 14-Aug-00 40.657
--------------------------------------------------------------------------------------------------------------------
20029.48 China 961108207 12-Jul-96 1-Mar-01 96110820.7
--------------------------------------------------------------------------------------------------------------------
20029.49 Abandoned Colombia 96036764 12-Jul-96
--------------------------------------------------------------------------------------------------------------------
20029.50 Czech Rep. PV 203696 9-Jul-96
--------------------------------------------------------------------------------------------------------------------
20029.51 Abandoned Eucador SP 961818 11-Jul-96 21-May-98 P1-981368
--------------------------------------------------------------------------------------------------------------------
20029.52 Abandoned Egypt 66096 11-Jul-96
--------------------------------------------------------------------------------------------------------------------
20029.53 Eurasia 199600048 12-Jul-96 3-Dec-97 000037
--------------------------------------------------------------------------------------------------------------------
20029.54 European Patent Office 962019436 11-Jul-96 18-Mar-98 0753512
--------------------------------------------------------------------------------------------------------------------
20029-55 Hungary P 9601918 12-Jul-96
--------------------------------------------------------------------------------------------------------------------
20029.56 Xxxxx 0000/XXX/00 12-Jul-96
--------------------------------------------------------------------------------------------------------------------
20029.57 Indonesia P 961950 8-Jul-96
--------------------------------------------------------------------------------------------------------------------
20029.58 Abandoned Israel 118815 8-JuI-96 29-Sep-00
--------------------------------------------------------------------------------------------------------------------
20029.59 Japan 1830581996 12-Jul-96
--------------------------------------------------------------------------------------------------------------------
20029.60 S Korea 280161996 11 Jul-96
--------------------------------------------------------------------------------------------------------------------
20029.61 Malaysia XX0000000 11-Jul-96
--------------------------------------------------------------------------------------------------------------------
20029.62 Xxxxxx 000000 12-Jul-96 29-Sep-00 198843
--------------------------------------------------------------------------------------------------------------------
20029.63 Xxx Xxxxxxx 000000 8-Jul-96 15-Jun-98 286951
--------------------------------------------------------------------------------------------------------------------
20029.64 Abandoned Nigeria 15396 10-Jul-96 6-Dec-96 12578
--------------------------------------------------------------------------------------------------------------------
20029-65 Norway 962931 12-Jul-96 6-Dec-99 306.672
--------------------------------------------------------------------------------------------------------------------
20029.66 Abandoned Pakistan 450/96 11-Jul-96 11-Nov-98 135353
--------------------------------------------------------------------------------------------------------------------
20029.67 Abandoned Xxxx 00000 12-Jul-96
--------------------------------------------------------------------------------------------------------------------
20029.68 Philippines 53652 8-Jul-96
--------------------------------------------------------------------------------------------------------------------
20029.69 Poland 315191 10-Jul-96
--------------------------------------------------------------------------------------------------------------------
20029-70 Romania 9601426 00-Xxx-00
--------------------------------------------------------------------------------------------------------------------
00000-00 Xxxxx Xxxxxx 96170188 30-Jul-96
--------------------------------------------------------------------------------------------------------------------
20029.72 Abandoned Singapore 96102355 8-Jul-96 22-Aug-00 43383
--------------------------------------------------------------------------------------------------------------------
20029.73 Abandoned Xxxxxx Xxx. XX 0 00000 0-Xxx-00 18-Jan-01
--------------------------------------------------------------------------------------------------------------------
20029.74 Abandoned S Africa 965883 11 Jul-96 26-Mar-97 965883
--------------------------------------------------------------------------------------------------------------------
20029.75 Abandoned Xxx Xxxxx 00000
--------------------------------------------------------------------------------------------------------------------
20
-------------------------------------------------------------------------------------------------------------------
Reference No. Territory Application No. Filing Date Issue Date Patent No. or
Publication
No.
-------------------------------------------------------------------------------------------------------------------
20029.76 Taiwan 85108324 10-Jul-96 21-Jan-01 126896
-------------------------------------------------------------------------------------------------------------------
20029.77 Abandoned Tangiers 1399 12-Jul-96
-------------------------------------------------------------------------------------------------------------------
20029.78 Thailand 32280 9-Jul-96
-------------------------------------------------------------------------------------------------------------------
20029.79 Turkey 9600579 12-Jul-96 22-Mar-99 TR 1996
00579 B
-------------------------------------------------------------------------------------------------------------------
20029.80 Abandoned United Arab Emirates 10796 13-Jul-96
-------------------------------------------------------------------------------------------------------------------
20029.81 Abandoned Ukraine 96072764 9-Jul-96
-------------------------------------------------------------------------------------------------------------------
20029.82 Abandoned Uruguay 24283 15-Jul-96
-------------------------------------------------------------------------------------------------------------------
20029.83 Venezuela 126096 12-Jul-96
-------------------------------------------------------------------------------------------------------------------
20029.84 Abandoned Vietnam SC 2696 12-Jul-96 29-Sep-00 1500
-------------------------------------------------------------------------------------------------------------------
20029.85 Austria 962019436 11-Jul-96 18-Mar-98 0753512
-------------------------------------------------------------------------------------------------------------------
20029.86 Belgium 962019436 11-Jul-96 18-Mar-98 0753512
-------------------------------------------------------------------------------------------------------------------
20029.87 Denmark 962019436 11 -Jul-96 18-Mar-98 0753512
-------------------------------------------------------------------------------------------------------------------
20029.88 Finland 962010436 11-Jul-96 18-Mar-98 0753512
-------------------------------------------------------------------------------------------------------------------
20029.89 France 962019436 11-Jul-96 18-Mar-98 0753512
-------------------------------------------------------------------------------------------------------------------
20029.90 Germany 962019436 11-Jul-96 18-Mar-98 0753512
-------------------------------------------------------------------------------------------------------------------
20029.91 Greece 962019436 11-Jul-96 18-Mar-98 3026998
-------------------------------------------------------------------------------------------------------------------
20029.92 Netherlands 962019436 11-Jul-96 18-Mar-98 0753512
-------------------------------------------------------------------------------------------------------------------
20029.93 Ireland 962019436 11-Jul-96 18-Mar-98 0753512
-------------------------------------------------------------------------------------------------------------------
20029.94 Italy 962019436 11-Jul-96 18-Mar-98 0753512
-------------------------------------------------------------------------------------------------------------------
20029.95 Luxembourg 962019436 11 -Ju1-96 18-Mar-98 0753512
-------------------------------------------------------------------------------------------------------------------
20029.96 Abandoned Morocco 24311 12-Jul-96
-------------------------------------------------------------------------------------------------------------------
20029.97 Portugal 962019436 11 Ju1-96 18-Mar-98 0753512
-------------------------------------------------------------------------------------------------------------------
20029.98 Spain 962019436 11-Jul-96 18-Mar-98 0753512
-------------------------------------------------------------------------------------------------------------------
20029.99 Sweden 962019436 11-Jul-96 18-Mar-98 0753512
-------------------------------------------------------------------------------------------------------------------
25029.40 Switzerland 962019436 11-Jul-96 18-Mar-98 0753512
-------------------------------------------------------------------------------------------------------------------
25029.41 Abandoned Hong Kong 991107432 18-Sep-98 11 -Jun-99 HK1010052
-------------------------------------------------------------------------------------------------------------------
25029.42 Great Britain 962019436 11-Jul-96 18-Mar-98 753512
-------------------------------------------------------------------------------------------------------------------
21
6. Title: Immunomodulatory azaspiranes
Priority Application: USSN 101,704 28 September 1987
--------------------------------------------------------------------------------------------------------------------
Reference No. Territory Application No. Filing Date Issue Date Patent No. or
Publication
No.
--------------------------------------------------------------------------------------------------------------------
20031.00 US 07/101,704 28-Sep-87
Abandoned
--------------------------------------------------------------------------------------------------------------------
20031.20 CIP US 07/244,229 13-Sep-88 16-Oct-90 US 4,963,557
20031.00
--------------------------------------------------------------------------------------------------------------------
20031.40 PCT PCT/US88/03323 27-Sep-88
--------------------------------------------------------------------------------------------------------------------
20031.41 Abandoned Bahamas 930 27-Sep-88 14-Apr-89 930
--------------------------------------------------------------------------------------------------------------------
20031.42 Canada 578528 27-Sep-88 26-Apr-93 1313189
--------------------------------------------------------------------------------------------------------------------
20031.43 China 881090328 27-Sep-88 21-Jan-96 881090328
--------------------------------------------------------------------------------------------------------------------
20031.44 Cyprus 883089146 26-Sep-88 12-Sep-96 1955
--------------------------------------------------------------------------------------------------------------------
20031.45 Czech Rep PV 397091 20-Dec-91
--------------------------------------------------------------------------------------------------------------------
20031.46 European Patent Office 883089146 26-Sep-89 30-Nov-94 0310321
--------------------------------------------------------------------------------------------------------------------
20031.47 Ireland 292998 28-Sep-88 16-Apr-96 67891
--------------------------------------------------------------------------------------------------------------------
20031.48 Xxxxxxxxx Xxxxxx 00000 25-Sep-88 21-Feb-93 87908
--------------------------------------------------------------------------------------------------------------------
20031.49 Abandoned Malaysia 8801078 27-Sep-88 30-Jul-94 104932
--------------------------------------------------------------------------------------------------------------------
20031.50 Mexico 923765 29-Jun-92 10-May-94 174367
--------------------------------------------------------------------------------------------------------------------
20031.51 Xxx Xxxxxxx 000000 27-Sep-88 13-Jun-91 226354
--------------------------------------------------------------------------------------------------------------------
20031.52 Pakistan 43988 28-Sep-88 26-Dec-90 131497
Abandoned
--------------------------------------------------------------------------------------------------------------------
20031.53 Portugal 88603 27-Sep-88 25-Jun-92 88603
--------------------------------------------------------------------------------------------------------------------
20031.54 Abandoned Xxxxxxxxx 00000000 26-Sep48 30-Nov-94 96914205
--------------------------------------------------------------------------------------------------------------------
20031.55 Slovakia 397097 20-Dec-91
--------------------------------------------------------------------------------------------------------------------
20031.56 Abandoned S Africa 887266 28-Sep-88 27-Jan-93 887266
--------------------------------------------------------------------------------------------------------------------
20031.57 Taiwan 77106657 24-Sep-88 26-Apr-91 43871
--------------------------------------------------------------------------------------------------------------------
20031.58 Abandoned Zimbabwe 12388 21-Sep-88 7-Apr-89 12388
--------------------------------------------------------------------------------------------------------------------
20031.59 Australia 2533388 27-Sep-88 1 -Jun-92 619780
--------------------------------------------------------------------------------------------------------------------
20031.60 Denmark 77090 27-Sep-88 8-May-95 170042
--------------------------------------------------------------------------------------------------------------------
20031.61 Finland 901530 27-Sep-88 10-Feb-95 93006
--------------------------------------------------------------------------------------------------------------------
20031.62 Abandoned Hungary 588988 27-Sep-88 24-Sep-93 208809
--------------------------------------------------------------------------------------------------------------------
20031.63 Japan 63508105 27-Sep-88 2 1-Nov-96 2582888
--------------------------------------------------------------------------------------------------------------------
20031.64 Abandoned S Korea 899-00907 27-Sep-88 22-Sep-98 166336
--------------------------------------------------------------------------------------------------------------------
20031.65 Norway 901392 27-Sep-88 9-Feb-94 173824
--------------------------------------------------------------------------------------------------------------------
20031.66 Philippines 37609 13-Sep-88 5-Nov-91 25812
--------------------------------------------------------------------------------------------------------------------
20031.67 Abandoned Hungary P/P00121 1-Jul-95 211325
--------------------------------------------------------------------------------------------------------------------
20031.68 Austria 883089146 26-Sep-88 30-Nov-94 0310321
--------------------------------------------------------------------------------------------------------------------
20031.69 Belgium 883089146 26-Sep-88 30-Nov-94 0310321
--------------------------------------------------------------------------------------------------------------------
20031.70 France 883089146 26-Sep-88 30-Nov-94 0310321
--------------------------------------------------------------------------------------------------------------------
20031.71 Germany 883089146 26-Sep-88 30-Nov-94 0310321
--------------------------------------------------------------------------------------------------------------------
20031.72 Great Britain 883089146 26-Sep-88 30-Nov-94 0310321
--------------------------------------------------------------------------------------------------------------------
20031.73 Greece 883089146 26-Sep-88 30-Nov-94 0310321
--------------------------------------------------------------------------------------------------------------------
20031.74 Italy 8830891 46 26-Sep-98 30-Nov-94 0310321
--------------------------------------------------------------------------------------------------------------------
22
-------------------------------------------------------------------------------------------------------------------
Reference No. Territory Application No. Filing Date Issue Date Patent No. or
Publication
No.
-------------------------------------------------------------------------------------------------------------------
20031.75 Luxembourg 883089146 26-Sep-88 30-Nov-94 0310321
-------------------------------------------------------------------------------------------------------------------
20031.76 Netherlands 883089146 26-Sep-88 30-Nov-94 0310321
-------------------------------------------------------------------------------------------------------------------
20031.77 Spain 883089146 26-Sep-88 30-Nov-94 0310321
-------------------------------------------------------------------------------------------------------------------
20031.78 Sweden 883089146 26-Sep-88 30-Nov-94 0310321
-------------------------------------------------------------------------------------------------------------------
20031.79 Abandoned Hong Kong 98105430 HK 1006274
-------------------------------------------------------------------------------------------------------------------
23
